与酒精相关的渐进性脑缩和白质病理与对mTOR信号传递的长期抑制作用有关
Ming Tong1, Camilla Homans2, William Pelit3
1Department of Medicine, Rhode Island Hospital, Brown University Health, and The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Biomolecules
|March 28, 2025
概括
长期使用酒精会损害大脑中的白质,影响髓和mTOR信号通路. 早期损伤显示蛋白质增加,而后期阶段抑制关键信号,影响髓维护和认知功能.
科学领域:
- 神经科学是一个神经科学.
- 毒理学 毒理学 毒理学
- 细胞生物学 细胞生物学
背景情况:
- 与酒精有关的脑损伤 (ARBD) 导致认知障碍和痴呆症,白质是主要目标.
- ARBD进展的机制,包括神经炎症和改变的细胞信号,需要进一步研究.
- 了解这些途径对于预防永久性残疾至关重要.
研究的目的:
- 调查慢性乙醇消费对白质髓蛋白表达的时间依赖性影响.
- 分析神经炎症标志物和机械点的拉巴素 (mTOR) 途径信号响应乙醇.
- 为了描述ARBD在白质中的进展,在8周的时间内.
主要方法:
- 成年长埃文斯大鼠接受了含有0%或36%乙醇的液体饮食.
- 实验组在1天到8周的时间点进行了分析.
- 额叶组织接受了他的病理学,分子和生物化学分析.
主要成果:
- 慢性乙醇摄入导致大脑显著缩4周,持续整个研究.
- 早期乙醇暴露 (≤2周) 全球增加了非髓化,髓化和星球细胞标志物.
- 晚期暴露 (6-8周) 降低了寡干细胞/髓蛋白/质蛋白表达,早期mTOR通路激活,随后是下游抑制.
结论:
- 随着时间的推移,乙醇暴露会对白质质蛋白和mTOR信号产生差异性影响,影响髓维护.
- mTOR信号的调节失调与ARBD的进展有关.
- 准mTOR通路可能对于保持白质完整性和预防ARBD认知衰退至关重要.
相关概念视频
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...


